AU2022283915A1 - Line-1 inhibitors as cognitive enhancers - Google Patents

Line-1 inhibitors as cognitive enhancers Download PDF

Info

Publication number
AU2022283915A1
AU2022283915A1 AU2022283915A AU2022283915A AU2022283915A1 AU 2022283915 A1 AU2022283915 A1 AU 2022283915A1 AU 2022283915 A AU2022283915 A AU 2022283915A AU 2022283915 A AU2022283915 A AU 2022283915A AU 2022283915 A1 AU2022283915 A1 AU 2022283915A1
Authority
AU
Australia
Prior art keywords
line
inhibitor
subject
administered
cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022283915A
Other languages
English (en)
Inventor
Andrew Satlin
Eckard Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transposon Therapeutics Inc
Original Assignee
Transposon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transposon Therapeutics Inc filed Critical Transposon Therapeutics Inc
Publication of AU2022283915A1 publication Critical patent/AU2022283915A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022283915A 2021-06-04 2022-06-03 Line-1 inhibitors as cognitive enhancers Pending AU2022283915A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163197015P 2021-06-04 2021-06-04
US63/197,015 2021-06-04
PCT/US2022/032120 WO2022256625A1 (en) 2021-06-04 2022-06-03 Line-1 inhibitors as cognitive enhancers

Publications (1)

Publication Number Publication Date
AU2022283915A1 true AU2022283915A1 (en) 2024-01-18

Family

ID=84323626

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022283915A Pending AU2022283915A1 (en) 2021-06-04 2022-06-03 Line-1 inhibitors as cognitive enhancers

Country Status (10)

Country Link
US (1) US20240285664A1 (https=)
EP (1) EP4346835A4 (https=)
JP (1) JP2024520132A (https=)
KR (1) KR20240017910A (https=)
CN (1) CN117813096A (https=)
AU (1) AU2022283915A1 (https=)
CA (1) CA3221190A1 (https=)
IL (1) IL309036A (https=)
MX (1) MX2023014381A (https=)
WO (1) WO2022256625A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250170158A1 (en) * 2022-02-22 2025-05-29 Rome Therapeutics, Inc. Methods of treating medical conditions using censavudine or a related compound
WO2023178128A1 (en) * 2022-03-15 2023-09-21 Rome Therapeutics, Inc. Methods of treating medical conditions using islatravir or a related compound
WO2024107850A1 (en) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds and their use in treating medical conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
EP3914604B1 (en) * 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
KR20230107543A (ko) * 2020-09-23 2023-07-17 트랜스포손 테라퓨틱스, 인코포레이티드 질병을 치료하기 위한 line-1 억제제

Also Published As

Publication number Publication date
MX2023014381A (es) 2023-12-15
CN117813096A (zh) 2024-04-02
EP4346835A4 (en) 2025-04-16
KR20240017910A (ko) 2024-02-08
IL309036A (en) 2024-02-01
EP4346835A1 (en) 2024-04-10
WO2022256625A1 (en) 2022-12-08
US20240285664A1 (en) 2024-08-29
JP2024520132A (ja) 2024-05-21
CA3221190A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
AU2022283915A1 (en) Line-1 inhibitors as cognitive enhancers
AU2015371255B2 (en) Fused pyrimidine compounds for the treatment of HIV
AU2024203833A1 (en) Benzamide compounds
US20240173346A1 (en) Line-1 inhibitors to treat cns and systemic diseases
EP4186496B1 (en) Application of cannabidiol in treatment of coronavirus infections
CN101990434A (zh) 用于治疗沙粒病毒感染的抗病毒药物
US9815827B2 (en) Agent for treatment of schizophrenia
WO2013040527A1 (en) Antimicrobial compounds
DK2555775T3 (en) Combination Compositions of Adenosine A1 Agonists and Carbonic Anhydrase Inhibitors to Reduce Intraocular Pressure
JP2009532497A (ja) 癌を処置するための治療剤の組合せ
JP2002534390A (ja) 癌治療におけるアデノシンアゴニスト類の使用
IL301122A (en) Compositions and methods for treating muscular dystrophies
JP2018002619A (ja) オートファジー阻害剤
EP3782620B1 (en) Pharmaceutical composition comprising 1,2-naphthoquinone derivative for use in preventing or treating acute myeloid or lymphoblastic leukemia
OA21831A (en) LINE-1 inhibitors to treat CNS and systemic diseases.
US20250115593A1 (en) Rocaglate derivatives and uses thereof
WO2023229685A2 (en) Broad-spectrum inhibitors of cytomegalovirus
EP2626073A1 (en) Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4)
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
US20240317717A1 (en) Sulfonamide compounds and the use thereof in the treatment of cancer
CA3152424A1 (en) Quinoline inhibitors of rad52 and methods of use
CA3205357A1 (en) Compounds and methods for treating malaria
HK40085142B (en) Application of cannabidiol in treatment of coronavirus infections
CA3119395A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
WO2017176777A1 (en) Bta-c585 for the treatment and/or prevention of conditions related to or associated with hyperuricemia or hyperuricosuria and other conditions